Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Up 46.9% in September

Vivos Therapeutics, Inc. (NASDAQ:VVOSGet Free Report) was the recipient of a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 93,600 shares, a growth of 46.9% from the September 15th total of 63,700 shares. Approximately 2.3% of the company’s shares are sold short. Based on an average daily trading volume, of 1,310,000 shares, the short-interest ratio is currently 0.1 days.

Vivos Therapeutics Stock Down 2.8 %

Vivos Therapeutics stock traded down $0.07 during trading hours on Monday, reaching $2.46. 46,260 shares of the company’s stock were exchanged, compared to its average volume of 523,778. The firm has a market capitalization of $7.94 million, a PE ratio of -0.23 and a beta of 7.72. The firm’s 50 day simple moving average is $2.66 and its 200 day simple moving average is $2.55. Vivos Therapeutics has a twelve month low of $1.91 and a twelve month high of $48.79.

Vivos Therapeutics (NASDAQ:VVOSGet Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.60) earnings per share for the quarter. The business had revenue of $4.05 million during the quarter. Vivos Therapeutics had a negative return on equity of 652.32% and a negative net margin of 85.90%. Analysts anticipate that Vivos Therapeutics will post -3.13 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets boosted their price target on shares of Vivos Therapeutics from $6.40 to $6.60 and gave the stock a “buy” rating in a research report on Tuesday, August 20th.

Read Our Latest Analysis on Vivos Therapeutics

About Vivos Therapeutics

(Get Free Report)

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.

Recommended Stories

Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.